Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07976016 Formulation A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | Participants will receive a single dose of PF-07976016 in up to 3 study periods. In sequence 1, participants will receive formulation A followed by formulation B. There will be 7 days between each dose as a wash out period. |
| Sequence 2 | EXPERIMENTAL | Participants will receive single doses of PF-07976016 in up to 3 study periods. In sequence 2, participants will receive formulation B followed by formulation A. There will be 7 days between each dose as a wash out period. |
| Name | Type | Description |
|---|---|---|
| PF-07976016 Formulation A | DRUG | PF-07976016; formulation A - current/reference |
| PF-07976016 Formulation B | DRUG | PF-07976016; Formulation B - new/test |
Key Inclusion Criteria: * Overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs and ECG assessments. * Willing to provide consent and follow study requirements * Total body weight \>110lbs (50kg) Key Exclusion Criteria: ...
PF-07976016 Formulation A is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development to evaluate how different forms of the study medicine are taken up into the blood. The drug is not approved and remains under investigation.
PF-07976016 Formulation A is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to study the drug's absorption in healthy adult volunteers.
PF-07976016 Formulation A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed.
PF-07976016 Formulation A has one completed Phase 1 trial, NCT06670170, titled "A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults." The trial enrolled 12 participants in the United States.
PF-07976016 Formulation A is a specific formulation of the study medicine PF-07976016. The clinical trial NCT06670170 evaluates how different forms of PF-07976016 are absorbed into the blood, with Formulation A being one of the forms studied.